Evogene Ltd.

Investor Presentation • Jan 9, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2024

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F☒Form 40-F☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1Evogene Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: January 9, 2024

By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

COMPANY PRESENTATION

January 9, 2024 Ofer Haviv, President & CEO

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statement in this presentation when it discusses its value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, its capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel such as further mobilizations or escalation in the northern boarder of Israel, and those risk factors contained in Evogene's reports filed with the applicable securities authority (including in its Annual Report on Form 20-F).

In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and preclinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections, and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

About Evogene

Business Model

Success Stories

Summary

Annex I - Financial overview Annex II - Evogene subsidiaries

OUR VISION

Revolutionize the development of life-science based products, utilizing cutting edge computational biology technologies

DECODING BIOLOGY

Life Science Product Development – Current State

Low probability of success with high cost and long time-to-market

*https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459; Phillips McDougall, 2016.

The Ultimate Case of Finding the "Needle in the Haystack"

The challenge: finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach successful products

The Opportunity

Utilizing advanced computational biology technologies

to discover and optimize the most promising candidates addressing multiple development challenges towards successful life-science based products

Increase probability of success

Reduce time

Reduce cost

Our Solution When Biology Meets Disruptive Technologies

Incorporating deep scientific understanding with big data and advanced AI technologies, to successfully discover & guide the optimization of novel life-science based products

– Computational Predictive Biology

Tailored AI Tech-Engines

The CPB platform directs and accelerates product discovery and optimization through dedicated AI Tech-Engines for products based on three core components:

• Microbes
• Small molecules
• Genetic elements

AI Tech-Engines to direct & accelerate product discovery & optimization

Discovery

Computational selection of the most promising candidates to initiate the product development process.

Optimization

Computational driven solution addressing optimization challenges for the selected candidates, without impairing their ability to address other product attributes.

AI Tech-Engine Dashboard

(Example)

Discovery	01 Dataset generation -----	V 02 Function prediction -----	03 Bacteria prediction	04 Mining and selection	05 Regulation & Patentability	06 Experimental validation	07 Experimental data analysis
(■)	Generate phylogenetic tree (8) CorBac Download public	Function	Function to Organism (F20) (@) Bacteria trait	Explore bacteria இ trait prediction results Explore F20	(日) APHIS compliance	(6) Experiment design	(ਬ Fungi experiments Phytium pipeline
0 genomes ම Generate	@ Explore Productions phenotype	exploration apps Cluster,EvoCOG,KEG G,BLAST,EvoCOG	(@) prediction (ML)	ල results Function (ව exploration apps	(日) Silva ( Patentability	(8) Fungi experiments Phytium pipeline (8) anlaysis	(9) anlaysis (भ Insecticide plant assays
				Strain exploration இ apps		Insecticide plant இ assays
				(Strain teaming		(Station1
AZZ	46,237 Integrated bacterial genomes 200,599,577 Proteins in our ortholog database	ה ה database 3	6,650,502 Ortholog groups in function 93,995 Ortholog-phenotype associations	CHECK NOW	Check the new app for EvoCOGs association with phenotypes Explore your bacteria for EvoCOGs linked to a specific phenotype , retrieve EvoCOGs linked to specific phenotypes or retrieve bacterial genomes with EvoCOGs linked to specific phenotypes.

Potential Market Diversity

Structuring an 'ecosystem' of diverse product types to be developed utilizing our AI Tech-Engines

Potential Markets for MicroBoost AI (Example)

Agenda

About Evogene

Success Stories

Summary

Annex I – Financial overview Annex II – Evogene subsidiaries

Evogene's AI Tech-Engines - Potential Markets

Business Strategy

Capture the value of our AI tech-engines as product-development enablers, through two types of business models:

Licensing

A time-limited license grant to utilize one of Evogene's tech-engines, to a third party for product development in a defined commercial field. In most cased the third party will be a subsidiary, or a related party, of Evogene.

Collaboration

Joint product development with leading companies utilizing Evogene's unique tech-engines. Typically, the partner leads later-stage development and product commercialization.

1 | Business Model Licensing

Licensing Evogene's AI Tech-Engines to a third party (currently, all Evogene subsidiaries)

Potential revenue stream

• License fees & R&D reimbursement
• Dividends to Evogene as a shareholder
• Significant one-time-payment upon an exit event*

Powered by:

*As long as Evogene remains a major shareholder

2 | Business Model Collaboration

Collaborations Driven by Evogene's AI Tech-Engines with Leading Life-Science Companies

Potential revenue stream

• Upfront payments
• R&D fees
• Milestone payments
• Royalties from sale of end-products

Powered by:

Licensing & Collaboration - Current Status

Agenda

About Evogene

Business Model

Summary

Annex I – Financial overview Annex II – Evogene subsidiaries

Mission

Improve food quality, sustainability and agricultural productivity through microbiome-based, ag-biological products

Ag-biologicals a rapidly growing market

The ag-biologicals market is expected to grow at a double digit CAGR over the next decade

Unique AI tech-platform and data assets

Proprietary tech platform increases probability of success and reduces cost and time-to-market

Powered by

Broad & diverse pipeline

8 programs – new product launch expected every 1-2 years

Strategic partners & investors

2 revenuegenerating graduated programs

Evogene's

Subsidiary Yalos™ - Bio-inoculant for cereal grains*

Sold in USA** & expanding globally

Superior performance

* Yalos™ has regulatory approval in the US & Canada for all small grains including wheat, barley, durum, oats, soybeans, canola, and others. Data was gathered in large side-by-side field trials in the US ** In 2023 Yalos™ was sold for wheat. 2023 trials for barley and durum look promising for potential 2024 expansion

MicroBoost AI tech-engine directing & accelerating product discovery & optimization

Increase probability of success

Reduce time and cost

LAV311 - Bio-pesticide for Fruit rots & Powdery mildew

Licensing agreement with

• \$5M upfront payment
• Future milestone payments
• Royalties from future sales

Superior performance

compared to competing biological control products, similar results to chemicals

Consistent performance

in preventative application over 3 years (validated by Corteva)

Chemical Untreated

Integrated spray programs showed a potential reduction of 3-5 chemical applications* per season

* Program consisted of alternating applications between a chemical and LAV311 across the season

MicroBoost AI tech-engine directing & accelerating product discovery & optimization

Increase probability of success

Reduce time and cost

Mission Provide elite castor seeds to the bio-based industries

Castor oil emerging market

The global castor oil & oil derivatives market is expected to reach \$2.06 billion by 2028* CAGR of 4.9%

Unique tech platform for elite varieties

Combining deep scientific know-how, genomic and phenotypic big-data, and computational technology for elite castor variety development

Powered by

Holistic ag-solution

Proprietary holistic agsolution: elite varieties, growth protocols, and novel mechanical harvesting and dehulling machines

Strategic alliance

A strategic alliance in the biofuel space with a leading global oil and gas company

3 Commercial revenue generating castor varieties

Proprietary varieties with improved traits suitable for commercial scale cultivation

EVF716, EVF712, EVF701

\*https://www.marketreportsworld.com/global-castor-oil-and-derivatives-market-19862171

EVF716, EVF712, EVF701 Elite Castor Varieties

Average plant helght (cm)	70-120cm
Flowering (days from sowing)	35-40 days
Total cycle (harvest) (days from sowing)	100-115 days
Receme size	Small
Number of Receme	4-5 racemes
Stern color	Dark red
Drought tolerance	LOW
Oll content (X)	48-50%
Grain yield posential (t/Ha)	2-3 t/Ha

cultivation®
Recommended herbicide	Pendimethallin
Hand weeding	Proceed when necessary
Fertillzers and liming	Follow local recommendation
Manual or mechanized harvesting	Fantini headers

Planting system	Pneumatic seeders
Spacing (continuous grooves)	0.75-1m among furrows
Plants / Hectare (Density)	38-42K
Seed consumption	13-15 kg/ha
Seeding depth	-5cm

teristics®		Technical Recommendations®
0	100-150 cm	Planting time	Early - mid rainy season
wing)	40-45 days	Planting system	Pneumatic seeders
(Dullangs Lugh St	120-140 days	Spacing (continuous grooves)	0.75-1 m among furrows
	Medium	Plants / Hectare (Density)	35-40k
	3-4 racemes	Seed consumption	10-14 kg/Ha
	Ught green	Seeding depth	~5cm
	Medium	"Varioty characteristics and highly subjechad to temporations, sun radiation and was availability
	48-50%
(a)	2-3 t/Ha
e	Pendimethalyn Proceed when necessary Follow local recommendation
	arvesting Fantini headers
by subjacted to temporature, ofly or Varieties PEVF716
03.FF			Info@casterra.

Average plant height (cm)		120-170 cm	Planting time
Flowering (days from sowing)	40-45 days		Planting system
Total cycle (harvest) (days from sowing)		125-145 days	Spacing (continuous g
Receme size	Large		Plants / Hectate (Dens
Number of Receme		1-3 racemes	Seed consumption
Stem color	Light red.		Seeding depth
Drought tolerance	High		*Varioty characteristics are h cut radiation and was per and
Oll content (X)	48-50%
	2-3 1/43
Cultivation®
	Pendimethalin
	Proceed when necessary
	Follow local recommendation
sun radiation and was r availability
Grain yield potential (t/Ha) "Variony characearisxics and highly subjocted to temporature, sun radiation and was noiselber rus Recommended herbicide Hand weeding Fertillzers and liming Manual or mechanized harvesting Fantini headers "Variouy characseristics and highly subjected to temperatura, Explore all Castor Varieties

Evogene's

Subsidiary Castor Seed Sales

\$2.2 Million

\$9.1 Million

GeneRator AI tech engine directing & accelerating product discovery & optimization

Increase probability of success

Reduce time and cost

* Representing 40,000 (200*200) line potential for breeding

Agenda

About Evogene

Business Model

Success Stories

Summary

Annex I – Financial overview Annex II – Evogene subsidiaries

The Evogene Group

142 Employees

As of Nov 13, 2023

Our vision

Revolutionize the development of life-science based products, utilizing cutting edge computational biology technologies

Our unique offering - 3 AI Tech-Engines to direct & accelerate product discovery and optimization:

• MicroBoost AI
• ChemPass AI
• GeneRator AI

Tech engine value proposition

• Increase probability of success
• Reduce time
• Reduce cost

Business strategy - Capture the value of our AI tech-engines through:

• Licensing to 3rd parities (mainly subsidiaries)
• Collaboration with world-leading partners

Current subsidiaries

• Biomica Human-microbiome based therapeutics
• Lavie Bio – Ag-biologicals
• AgPlenus – Ag-chemicals
• Canonic - Medical cannabis
• Casterra – Castor end-to-end solution

Commercial products developed utilizing Evogene's AI tech-engines (examples)

• 3 commercial castor elite varieties by Casterra
• 2 ag-biologicals by Lavie Bio
• Medical cannabis products by Canonic

Vote of confidence

Equity investment in the following subsidiary:

• Lavie Bio Corteva & ICL
• Biomica Shanghai Healthcare Capital

THANK YOU!

Annex I: Financial Overview

Key Financials: Balance Sheet

Key Points:

• Consolidated cash position: ~\$37 million as of 30.09.2023
• This Consolidated cash position does not include the \$2.5 million, which represents the second half of the upfront payment from the licensing agreement of Lavie Bio with Corteva and amount due to the purchase orders received by Casterra in the last few months.
• No bank debt
• Listed on TASE (2007) and NASDAQ (2016)

Thousands of US \$	30.09.2023	31.12.2022
Current Assets	40,555	37,751
Long-Term Assets	17,191	18,375
Total Assets	57,746	56,126
Current Liabilities	6,484	5,625
Long-Term Liabilities (inc. \$10m convertible SAFE at Lavie Bio)	15,399	15,711
Equity attributable to equity holders of the Company	18,510	27,930
Non-controlling interest	17,353	6,860
Total Liabilities & Shareholders Equity	57,746	56,126

Annex II: Evogene Subsidiaries

Evogene Subsidiaries

76%*	70%*	98%*	100%*	100%*
Microbiome-based Therapeutics	Ag Biologicals	Ag Chemicals	Medical Cannabis	Castor Cultivation End-to-End Solution
Immuno-oncology •	Bio-stimulants •	High yield & consumer • Herbicides •	Elite castor varieties •
GI- related disorders •	Bio-pesticides •	Fungicides •	traits • Cultivation protocols • Therapeutic traits – • Harvesting and currently inflammation dehulling machinery & pain customized to Casterra's varieties
\$20M investment led by SHC (Apr. 2023)	\$27M investment (Aug 2019)** \$10M SAFE investment (Aug 2022)	• Insecticides

*Evogene holdings

**Includes \$10M cash investment along with transfer of assets

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology

Products & Pipeline

Immuno-oncology program

• Combination therapy for cancer with checkpoint inhibitors
• Phase 1 clinical stage
• Addressable market of \$309.7B (by 2030*)

GI related disorders

• Inflammatory Bowel Disorder (IBD) pre-clinical stage
• Irritable Bowel Syndrome (IBS) pre-clinical stage
• Addressable market: IBD \$27B; IBS \$3.3B (by 2026**)

Antimicrobial resistance (AMR)

• Clostridium Difficile Infection (CDI) discovery stage
• Methicillin-resistant Staphylococcus aureus (MRSA) discovery stage
• Addressable market: CDI \$1.7B (***); MRSA \$1.3B (by 2026****)

Expected upcoming value drivers

Immuno-oncology

▪ Readout & completion of POC from first in-human study; Pre-IND meeting with FDA

IBD

▪ Clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA.

IBS

▪ Advancement of pre-clinical studies and nomination of bacterial consortium for clinical trial

\*https://www.alliedmarketresearch.com/cancer-immunotherapy-market

*\*https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm\_source=blog.goo.ne.jp&utm\_medium=referral&utm\_campaign=Vrushali\_7Aug\_hc\_InflammatoryBowelDiseaseTreatmentMarket\_pr&utm\_content=Content; https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026, https://www.bloomberg.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-cagr-10-1-grand-view-research-inc

*** https://www.globaldata.com/media/press-release/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/

**** https://www.biospace.com/article/releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-surpass-us-1-3-billion-by-2026/

Example Results:

Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

Mission:

Improve food quality, sustainability & agriculture productivity through microbiome based ag-biologicals technology & products

Products & Pipeline (examples)

Bio-stimulants

1885=	t

• Yalos™ primarily spring wheat: commercial stage; addressable USA & Canada markets ~25M acres*
• Bio-stimulants #2 primarily soy: pre-development stage; addressable market ~90M acres*

Bio-pesticides

• Fruit rots primarily grapes: pre-commercial; addressable market >\$1B**
• Downy Mildew fruits and vegetables; development stage 1; addressable market >\$500M**
• Seedling disease corn and soy: pre-development; addressable market >\$500M**

Expected upcoming value drivers

Bio-stimulants

▪ Yalos™ – distribution licensing agreements and sales expansion in USA & Canada. Expansion to additional crops and an additional territory in 2025

Bio-pesticides:

• US regulatory approval for bio-fungicide candidate for fruit rots (LAV311) expected by 2024
• Submission for Lavie Bio's bio-fungicide candidate for downy mildew (LAV321) to the US EPA for regulatory approval – expected by 2025
• Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company – expected by 2025

\*https://www.fao.org/faostat/en/#home; https://www.nass.usda.gov/Charts\_and\_Maps/Crops\_County/;https://data.oecd.org/agroutput/crop-production.htm **Company estimation

Example Results:

• Yalos™ inoculant for spring wheat
• - LAV 311 bio-fungicide candidates for fruit rot

Lavie Bio's wheat field in the USA during harvest –

Sales initiated in 2022

Example of treatment against Botrytis Cinerea vs untreated control in vines

• License for LAV 311 & LAV 312 bio-fungicide candidates
• \$5M initial payment
• Additional future milestone payments & royalties

Mission:

Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology

Products & Pipeline

Herbicides

• Novel Mode-of-Action selective herbicide
• Herbicides addressable market \$48.9B (2027)*

Fungicides

• Novel Mode-of-Action wheat blotch fungicide
• Fungicides addressable market \$25.81B**

Insecticides

• Novel Site-of-Action resistance breaking piercing/sucking insecticide
• Insecticides addressable market \$22B (2030)***

*** https://straitsresearch.com/report/insecticides-market

Expected upcoming value drivers

Herbicides

• Milestone achievement of the ongoing collaboration with Corteva
• Engage in a new additional strategic collaboration

Fungicides

• Nominate new Mode-of-Action protein targets
• Initial greenhouse readouts of designed compounds on the defined fungi targets

Platform

• Verification of computational tool for selection of novel Mode-of-Action protein targets
• POC for the computational tool for novel molecule design

^\* https://www.statista.com/statistics/1350387/herbicides-market-size-globally/

^** https://www.fortunebusinessinsights.com/fungicides-market-103267

Powered by

Example Results:

New MoA Herbicide – APH1

Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1

Greenhouse testing of APH1 – Conferring resistance by modifying tobacco

| Biobased Materials Powered by

Mission:

Leading the castor oil market with an integrated solution for industrialized cultivation of castor in support of the biobased materials industry

Product & Pipeline

Elite castor seed varieties

• 'EVF' series castor seed suitable for various environmental and climatic conditions
• Estimated addressable castor oil market \$1.21B (2021) and is expected to expand at CAGR of 5.8% from 2022 to 2030*
• Main target markets:
  • Bio-polymers – driven by the need for quality and consistent inputs
  • Bio-fuel – driven by environmental & regulatory trends in EU

Agro-technical support

▪ Cultivation protocols to maximize the results of the elite seeds

Dedicated machinery

• Best-in-class harvesting header, developed with Fantini Srl., Italy
• Casterra proprietary patented dehulling machine

*https://www.grandviewresearch.com/industry-analysis/castor-oil-derivatives-industry

Expected upcoming value drivers

Seeds development

• Production extending production outreach in the target markets: Africa (Zambia & Kenya), Latin America (Brazil) with few hundred tons a year as of 2024
• R&D development of new seed traits matching industry needs (e.g., Ricin free, low viscosity) using advanced technologies: CRISPR, genetic markers

Territorial expansion

• Africa engaging with bio-fuel strategic industry leaders to increase our sales and sector footprint
• Latin America addressing the bio-polymer industry's interest in broad, consistent and high-quality castor oil supply in Latin America

Strategic alliance

▪ A strategic alliance with a leading global biofuel company, leveraging Casterra's holistic industrial solution

| Biobased Materials Powered by

High Yield & Oil Castor Seeds

Elite castor seed varieties – The 'EVF' series

Dedicated machinery

Castor growth protocol Mechanical Harvest Proprietary dehulling machine